Jan Pegg

Henry Ford Health System — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

9h-index1.3kcitations16works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(9), CAR-T cell therapy research(3), Cancer Research and Treatments(3), Prostate Cancer Treatment and Research(2), Complementary and Alternative Medicine Studies(2)

Publications16 total

Prospective Randomized Phase 2 Trial of Intensity Modulated Radiation Therapy With or Without Oncolytic Adenovirus-Mediated Cytotoxic Gene Therapy in Intermediate-Risk Prostate Cancer
International Journal of Radiation Oncology*Biology*Physics·2014· 81 cited
Feasibility of Adenovirus-Mediated hNIS Gene Transfer and 131I Radioiodine Therapy as a Definitive Treatment for Localized Prostate Cancer
Molecular Therapy·2011· 51 citedOpen Access
Acupuncture Versus Venlafaxine for the Management of Vasomotor Symptoms in Patients With Hormone Receptor–Positive Breast Cancer: A Randomized Controlled Trial
Journal of Clinical Oncology·2009· 222 citedOpen Access
Acupuncture for the Treatment of Vasomotor Symptoms in Breast Cancer Patients Receiving Hormone Suppression Treatment
International Journal of Radiation Oncology*Biology*Physics·2008· 4 cited
Phase I Study of Noninvasive Imaging of Adenovirus-mediated Gene Expression in the Human Prostate
Molecular Therapy·2008· 140 citedOpen Access
Phase I Trial of Replication-competent Adenovirus-mediated Suicide Gene Therapy Combined with IMRT for Prostate Cancer
Molecular Therapy·2007· 145 citedOpen Access
Five-year Follow-up of Trial of Replication-competent Adenovirus-mediated Suicide Gene Therapy for Treatment of Prostate Cancer
Molecular Therapy·2007· 108 citedOpen Access
83 Clinical trials combining oncolytic viral therapy and suicide gene therapy with conformalradiotherapy
Radiotherapy and Oncology·2006
724. Phase I Study of Replication-Competent Adenovirus-Mediated Suicide Gene Therapy in Combination with Conformal Radiotherapy for the Treatment of Intermediate- to High-Risk Prostate Cancer: Two Year Efficacy Results
Molecular Therapy·2006· 2 citedOpen Access
Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.
PubMed·2003· 265 cited
Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer.
PubMed·2002· 312 cited
Combined suicide gene therapy and radiotherapy for prostate cancer: A phase I study
International Journal of Radiation Oncology*Biology*Physics·2000· 1 cited
The placebo response: friend or foe?
Journal of Clinical Pharmacy and Therapeutics·1995
The placebo response: friend or foe?
Journal of Clinical Pharmacy and Therapeutics·1995· 1 cited
Hana kai ii: a 17-day dry saturation dive at 18.6 ATA. V. Maximal oxygen uptake.
Munich Personal RePEc Archive (Ludwig Maximilian University of Munich)·1977· 6 cited
Ventilatory response to hypoxia in acutely polycythemic dogs
Journal of Applied Physiology·1969· 11 cited

Frequent Co-authors

Svend O. Freytag(10), Hans Stricker(10), Mei Lü(8), Jae Ho Kim(7), James O. Peabody(6), Kenneth Barton(6), Benjamin Movsas(5), Yingshu Zhang(4), Stephen L. Brown(4), Mariza DePeralta-Venturina(3), Dell Paielli(3), Stephen L. Brown(3), I. Aref(3), Mohamed A. Elshaikh(3), Mark S. Khil(2), Eleanor Walker(2), Alba I. Rodríguez(2), Beth Kohn(2), Robert A. Levine(2), Kastytis C. Karvelis(2)